fluorodeoxyglucose f18 has been researched along with Malignant Mesothelioma in 57 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 34 (59.65) | 24.3611 |
| 2020's | 23 (40.35) | 2.80 |
| Authors | Studies |
|---|---|
| Kan, Y; Wang, W; Wang, Y; Xu, Y; Yang, J | 1 |
| Fendler, WP; Ferdinandus, J; Hautzel, H; Herrmann, K; Maier, S; Metzenmacher, M; Plönes, T; Sandach, P; Seifert, R | 1 |
| Kandathil, A; Subramaniam, RM | 1 |
| Castello, A; Lopci, E; Mansi, L | 1 |
| Agackiran, Y; Aloglu, M; Atikcan, S; Cimen, F; Düzgün, S; Senturk, A | 1 |
| Cheng, C; Dong, A; Zhao, B; Zuo, C | 1 |
| Inoue, F; Kamikawa, Y; Mori, M; Nishikawa, T; Okabayashi, T; Takahashi, M | 1 |
| Ahuja, J; Carter, BW; Gladish, GW; Marom, EM; Shroff, GS; Strange, CD; Truong, MT | 1 |
| Aigner, RM; Brcic, L; Fuchsjäger, M; Pernthaler, B; Talakic, E | 1 |
| Hu, S; Li, J; Yang, J | 1 |
| Büyükdeniz, MP; Can, C; Ebinç, S; Gündoğan, C; Güzel, Y; Kaplan, İ; Kepenek, F; Kömek, H; Oruç, Z | 1 |
| Hou, G; Jin, Y; Peng, P; Zheng, R | 1 |
| Doi, H; Kijima, T; Kitajima, K; Kuribayashi, K; Yamakado, K | 1 |
| Alloisio, M; Bottoni, E; Castello, A; Ceresoli, GL; Crepaldi, A; Ferraroli, GM; Lopci, E; Novellis, P; Perrino, M; Rahal, D; Testori, A; Veronesi, G; Voulaz, E; Zucali, PA | 1 |
| Hashimoto, J; Ichikawa, T; Ikoma, H; Kodama, E; Kodama, T | 1 |
| Bejuy, O; Colin, DJ; Germain, S; Serre-Beinier, V; Triponez, F | 1 |
| Acevedo Báñez, I; Fernández-Rodríguez, P; Jiménez-Hoyuela García, JM; Martín-Marcuartu, JJ; Masero Carretero, JM | 1 |
| Wang, W; Xie, P; Yang, J | 1 |
| Boldorini, R; Filice, A; Lococo, F; Paci, M; Rapicetta, C; Rena, O; Torricelli, F; Versari, A | 1 |
| Ahn, MJ; Choi, JY; Han, J; Im, Y; Jeong, BH; Jhun, BW; Kim, H; Kim, J; Kwon, OJ; Lee, K; Lim, JH; Park, HY; Um, SW; Yoo, H | 1 |
| Kobayashi Shimizu, S; Koyama, K; Nishida, N; Okamura, T; Seura, H | 1 |
| Cao, J; Chen, Y; Hu, J; Xu, T; Zhang, X | 1 |
| Demirağ, F; Demiröz, ŞM; Özmen, Ö; Tatci, E; Tazeler, Z | 1 |
| Bello-Arqués, P; Bernal-Vergara, JC; Olivan-Sasot, P; Ruiz-Llorca, C; Utrera-Costero, A; Vera-Pinto, VJ; Yepes-Agudelo, AM | 1 |
| Etem, H; Gündoğan, C; Güzel, Y; Kaplan, İ; Kömek, H | 1 |
| Doi, H; Fujimoto, E; Kanemura, S; Kijima, T; Kitajima, K; Kuribayashi, K; Mikami, K; Nakano, T; Negi, Y | 1 |
| Bombardieri, E; Bonifacio, C; Bonomi, M; Ceresoli, GL; Chiti, A; Ciocia, G; De Vincenzo, F; Gianoncelli, L; Giordano, L; Lopci, E; Lorenzi, E; Perrino, M; Santoro, A; Setti, LR; Simonelli, M; Zucali, PA | 1 |
| Akamine, T; Haratake, N; Kozuma, Y; Maehara, Y; Matsubara, T; Nabeshima, K; Okamoto, T; Shoji, F; Takamori, S; Toyokawa, G; Yamada, Y | 1 |
| Braybrooke, JP; Darby, M; Hall, DO; Harvey, JE; Hooper, CE; Lyburn, ID; Masani, V; Maskell, NA; Searle, J; White, P | 1 |
| Bradbury, P; Cho, J; de Perrot, M; Elliott, HS; Hussey, D; Metser, U; Noam, T; Veit-Haibach, P | 1 |
| Betancourt, SL; Carter, BW; Lichtenberger, JP; Shroff, GS | 1 |
| Broggi, S; Calandrino, R; Cattaneo, M; Cuzzocrea, M; Dell'Oca, I; Di Muzio, N; Fiorino, C; Fodor, A; Gianolli, L; Incerti, E; Mapelli, P; Pasetti, M; Picchio, M; Samanes Gajate, AM | 1 |
| Aluja Jaramillo, F; Bhalla, S; Gutierrez, F | 1 |
| Broggi, S; Calandrino, R; Cattaneo, MG; Dell'Oca, I; Di Muzio, N; Fiorino, C; Fodor, A; Gianolli, L; Incerti, E; Pasetti, M; Passoni, P; Picchio, M; Samanes Gajate, AM | 1 |
| Balink, H; Edel, JP | 1 |
| Arrieta, O; Izquierdo-Sánchez, V; Medina, LA; Muñiz-Hernández, S; Pacheco-Yepez, J; Romero-Piña, ME; Vázquez-Becerra, H | 1 |
| Aoyagi, K; Kishida, Y; Koyama, H; Ohno, Y; Seki, S; Yoshikawa, T; Yui, M | 1 |
| Ishii, S; Ishii, Y; Kaburagi, T; Nakano, T | 1 |
| Dong, A; Dong, H; Zuo, C | 1 |
| Castellucci, P; Ferretti, A; Fuccio, C; Marzola, MC; Rubello, D; Spinapolice, EG; Trifirò, G | 1 |
| Brocken, P; de Geus-Oei, LF; Dekhuijzen, PN; Peters-Bax, L; van der Heijden, HF | 1 |
| Fujikawa, A; Kosuda, S; Kyoto, Y; Nakamori, T; Nakamori, Y; Naoi, Y | 1 |
| Barrington, SF; Chicklore, S; Cook, GJ; Goh, V; Klabatsa, A; Lang-Lazdunski, L | 1 |
| Endo, M; Kaira, K; Kenmotsu, H; Murakami, H; Naito, T; Nakajima, T; Ohde, Y; Ono, A; Takahashi, T; Yamamoto, N | 1 |
| Fukui, T; Ishiguro, F; Kawaguchi, K; Nakamura, S; Taniguchi, T; Usami, N; Yokoi, K | 1 |
| Bærentzen, S; Madsen, GA; Rasmussen, TR | 1 |
| Domènech-Vilardell, A; Ichise, M; Rasiej, MJ; Taub, RN | 1 |
| Le, BB; Nguyen, BD | 1 |
| Astoul, P; Dutau, H; Laroumagne, S; Loundou, A; Lucchini, S; Maldonado, F; Pinelli, V; Roca, E | 1 |
| Francis, RJ; Lee, YC; Millward, MJ; Morandeau, L; Nowak, AK; Segal, A; Segard, T | 1 |
| Doi, H; Kitajima, K; Kuribayashi, K | 1 |
| Akin, O; Arslan, A; Deniz, E; Ozcakir-Tomruk, C | 1 |
| Chillura, I; Migliore, M; Milazzotto, R; Militello, C; Pagana, A; Pergolizzi, S; Privitera, G; Raffaele, L; Salamone, V; Spatola, C; Tocco, A | 1 |
| Botticella, A; Coolen, J; De Ruysscher, D; Defraene, G; Deroose, CM; Nackaerts, K; Nafteux, P; Peeters, S; Ricardi, U | 1 |
| Doi, H; Fukushima, K; Hasegawa, S; Hashimoto, M; Hirota, S; Kitajima, K; Kuribayashi, K; Nakano, T; Tanooka, M; Tsuchitani, T | 1 |
| Doi, H; Funaguchi, N; Hasegawa, S; Kanemura, S; Kitajima, K; Kuribayashi, K; Mikami, K; Nakano, T; Shibata, E | 1 |
| Fukuoka, K; Hasegawa, S; Miyata, Y; Nakano, T; Okada, M; Takuwa, T; Tsutani, Y | 1 |
8 review(s) available for fluorodeoxyglucose f18 and Malignant Mesothelioma
| Article | Year |
|---|---|
Prognostic value of 18F-FDG PET/CT in malignant pleural mesothelioma: a meta-analysis.
Topics: Fluorodeoxyglucose F18; Humans; Mesothelioma, Malignant; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Tumor Burden | 2023 |
A Role for PET/CT in Response Assessment of Malignant Pleural Mesothelioma.
Topics: Fluorodeoxyglucose F18; Humans; Mesothelioma; Mesothelioma, Malignant; Pleural Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography | 2022 |
FDG PET/CT for Primary Staging of Lung Cancer and Mesothelioma.
Topics: Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2022 |
FDG PET/CT for Staging and Restaging Malignant Mesothelioma.
Topics: Fluorodeoxyglucose F18; Humans; Mesothelioma; Mesothelioma, Malignant; Pleural Neoplasms; Positron Emission Tomography Computed Tomography | 2022 |
MR Imaging of Pleural Neoplasms.
Topics: Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Mesothelioma; Mesothelioma, Malignant; Neoplasm Staging; Pleural Neoplasms; Positron-Emission Tomography; Tomography, X-Ray Computed | 2018 |
Pleural tumours and tumour-like lesions.
Topics: Diagnosis, Differential; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Neoplasm Staging; Pleura; Pleural Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2018 |
¹⁸F-FDG-PET/CT in malignant mesothelioma.
Topics: Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Tomography, X-Ray Computed | 2013 |
Present and future roles of FDG-PET/CT imaging in the management of malignant pleural mesothelioma.
Topics: Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Pleura; Pleural Neoplasms; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals | 2016 |
2 trial(s) available for fluorodeoxyglucose f18 and Malignant Mesothelioma
| Article | Year |
|---|---|
In-vivo imaging of methionine metabolism in patients with suspected malignant pleural mesothelioma.
Topics: Adult; Aged; Aged, 80 and over; Carbon Radioisotopes; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Methionine; Middle Aged; Positron Emission Tomography Computed Tomography | 2019 |
18F-Fluorodeoxyglucose PET/CT and dynamic contrast-enhanced MRI as imaging biomarkers in malignant pleural mesothelioma.
Topics: Aged; Aged, 80 and over; Contrast Media; Disease Progression; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Magnetic Resonance Imaging; Male; Mesothelioma; Mesothelioma, Malignant; Positron Emission Tomography Computed Tomography; Survival Analysis | 2018 |
47 other study(ies) available for fluorodeoxyglucose f18 and Malignant Mesothelioma
| Article | Year |
|---|---|
Factors affecting the life expectancy in malignant pleural mesothelioma: Our 10 years of studies and experience.
Topics: Female; Fluorodeoxyglucose F18; Humans; Life Expectancy; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Pleural Diseases; Pleural Neoplasms; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed | 2022 |
68 Ga-FAPI-04 Versus 18 F-FDG PET/CT in Detection of Epithelioid Malignant Pleural Mesothelioma.
Topics: Fluorodeoxyglucose F18; Gallium Radioisotopes; Humans; Mesothelioma, Malignant; Pleural Neoplasms; Positron Emission Tomography Computed Tomography; Quinolines | 2022 |
[Primary Pericardial Malignant Mesothelioma:Report of a Case].
Topics: Aged; Calbindin 2; Claudin-4; Female; Fluorodeoxyglucose F18; Heart Neoplasms; Humans; Keratins; Lung Neoplasms; Mediastinal Neoplasms; Mesothelioma; Mesothelioma, Malignant; Thymus Neoplasms | 2022 |
Imaging of Malignant Pleural, Pericardial, and Peritoneal Mesothelioma.
Topics: Fluorodeoxyglucose F18; Humans; Mesothelioma; Mesothelioma, Malignant; Neoplasm Staging; Pericardium; Pleura; Pleural Neoplasms; Positron Emission Tomography Computed Tomography | 2023 |
18F-FDG PET/CT in Primary Mesothelioma of the Liver.
Topics: Female; Fluorodeoxyglucose F18; Humans; Liver; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography | 2023 |
Malignant Peritoneal Mesothelioma With Butterfly-Shaped Muscle Metastasis: 68Ga-FAPI PET/CT Versus 18F-FDG PET/CT.
Topics: Fluorodeoxyglucose F18; Humans; Mesothelioma, Malignant; Muscles; Peritoneal Neoplasms; Positron Emission Tomography Computed Tomography | 2023 |
Comparison of the role of 18 F-fluorodeoxyglucose PET/computed tomography and 68 Ga-labeled FAP inhibitor-04 PET/CT in patients with malignant mesothelioma.
Topics: Fluorodeoxyglucose F18; Gallium Radioisotopes; Humans; Mesothelioma, Malignant; Positron Emission Tomography Computed Tomography; Prospective Studies; Quinolines; Tomography, X-Ray Computed | 2023 |
Ovarian Metastasis From Diffuse Epithelioid Malignant Mesothelioma Revealed by 18 F-FDG PET/CT.
Topics: Adult; Female; Fluorodeoxyglucose F18; Humans; Mesothelioma; Mesothelioma, Malignant; Ovarian Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography | 2023 |
Development of a Novel Prognostic Risk Classification System for Malignant Pleural Mesothelioma.
Topics: Adult; Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Glycolysis; Humans; Hydro-Lyases; Lymphocytes; Male; Mesothelioma, Malignant; Middle Aged; Neoplasm Grading; Neutrophils; Nomograms; Pleural Neoplasms; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Retrospective Studies; Risk Assessment; Survival Rate; Tumor Burden | 2020 |
18F-FDG Uptake of Localized Malignant Peritoneal Mesothelioma.
Topics: Aged; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Peritoneal Neoplasms; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals | 2020 |
Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Mice, Nude; Organ Size; Pleural Neoplasms; Positron Emission Tomography Computed Tomography; Xenograft Model Antitumor Assays | 2019 |
99mTc-HDP Bone Scintigraphy, SPECT/CT, and 18F-FDG PET/CT Diagnosis Imaging of Incidental Pleural Mesothelioma in a Patient With Biochemical Recurrences of Prostate Cancer: Is it Really a Coincidence?
Topics: Aged; Diphosphonates; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Organotechnetium Compounds; Pleural Neoplasms; Positron Emission Tomography Computed Tomography; Prostatic Neoplasms; Radiopharmaceuticals; Single Photon Emission Computed Tomography Computed Tomography | 2020 |
Tongue metastasis was the first sign of malignant pleural mesothelioma detected by PET/CT.
Topics: Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Pleural Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Tongue | 2020 |
18F-fluorodeoxyglucose positron emission tomography in malignant pleural mesothelioma: diagnostic and prognostic performance and its correlation to pathological results.
Topics: Aged; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Neoplasm Staging; Pleural Neoplasms; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Reproducibility of Results | 2020 |
Prognostic value of SUVmax on 18F-fluorodeoxyglucose PET/CT scan in patients with malignant pleural mesothelioma.
Topics: Aged; Combined Modality Therapy; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Pleural Neoplasms; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; ROC Curve; Survival Rate | 2020 |
A Case of Localized Malignant Peritoneal Mesothelioma With Lung Cancer Detected by 18F-FDG PET/CT.
Topics: Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Peritoneal Neoplasms; Positron Emission Tomography Computed Tomography | 2020 |
A Case of Localized Malignant Peritoneal Mesothelioma Evaluated by 18F-FDG PET/CT.
Topics: Aged; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Peritoneal Neoplasms; Positron Emission Tomography Computed Tomography; Prognosis | 2020 |
Is 18F-FDG PET/CT capable of differential diagnosis from tuberculous pleurisy from malignant mesothelioma?
Topics: Adult; Aged; Diagnosis, Differential; Fluorodeoxyglucose F18; Humans; Male; Mesothelioma, Malignant; Middle Aged; Positron Emission Tomography Computed Tomography; Retrospective Studies | 2021 |
The value of
Topics: Fluorodeoxyglucose F18; Humans; Mesothelioma, Malignant; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals | 2022 |
68Ga-FAPI-04 PET/CT Versus 18F-FDG PET/CT in Malignant Peritoneal Mesothelioma.
Topics: Aged, 80 and over; Fluorodeoxyglucose F18; Humans; Male; Mesothelioma, Malignant; Peritoneum; Positron Emission Tomography Computed Tomography; Quinolines | 2022 |
First-line chemotherapy with pemetrexed plus cisplatin for malignant peritoneal mesothelioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Pemetrexed; Pleural Neoplasms; Positron-Emission Tomography; Retrospective Studies; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2017 |
Prognostic and predictive role of [
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Neoplasm Staging; Pemetrexed; Pleurodesis; Positron-Emission Tomography; Prognosis; Tomography, X-Ray Computed; Treatment Outcome | 2017 |
A Case of the Resected Lymphohistiocytoid Mesothelioma: BAP1 Is a Key of Accurate Diagnosis.
Topics: Aged, 80 and over; Biomarkers, Tumor; Diagnosis, Differential; Fluorodeoxyglucose F18; Humans; Immunohistochemistry; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Positron-Emission Tomography; Tomography, X-Ray Computed; Tumor Suppressor Proteins; Ubiquitin Thiolesterase | 2017 |
Topics: Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pleural Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Survival Analysis; Tertiary Care Centers; Tomography, X-Ray Computed | 2018 |
FDG PET-derived parameters as prognostic tool in progressive malignant pleural mesothelioma treated patients.
Topics: Adult; Aged; Aged, 80 and over; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Radiopharmaceuticals | 2018 |
Moderately Hypofractionated Helical IMRT, FDG-PET/CT-guided, for Progressive Malignant Pleural Mesothelioma in Patients With Intact Lungs.
Topics: Adult; Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Humans; Lung; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Pleural Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiation Dose Hypofractionation; Radiotherapy, Intensity-Modulated; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2019 |
18F-FDG PET/CT Revealing Constrictive Pericarditis as the Only Manifestation of Malignant Mesothelioma.
Topics: Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Pericarditis, Constrictive; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals | 2019 |
Biodistribution and Tumor Uptake of
Topics: Animals; Antibodies, Monoclonal, Humanized; Cell Line, Tumor; Fluorodeoxyglucose F18; Gallium Radioisotopes; Humans; Imaging, Three-Dimensional; Liver; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Mice, Nude; Pleural Neoplasms; Positron Emission Tomography Computed Tomography; Tissue Distribution; Tomography, Emission-Computed, Single-Photon; Xenograft Model Antitumor Assays | 2018 |
Whole-Body MRI: Comparison of Its Capability for TNM Staging of Malignant Pleural Mesothelioma With That of Coregistered PET/MRI, Integrated FDG PET/CT, and Conventional Imaging.
Topics: Aged; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Multimodal Imaging; Neoplasm Staging; Pleural Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Whole Body Imaging | 2019 |
Usefulness of new flex-rigid pleuroscopy in the diagnosis of malignant pleural mesothelioma.
Topics: Aged, 80 and over; Biopsy; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Pleural Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Thoracoscopy; Tomography, X-Ray Computed | 2019 |
Multiple primary hepatic malignant mesotheliomas mimicking cystadenocarcinomas on enhanced CT and FDG PET/CT.
Topics: Cystadenocarcinoma; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Tomography, X-Ray Computed | 2014 |
High performance of F-fluorodeoxyglucose positron emission tomography and contrast-enhanced CT in a rapid outpatient diagnostic program for patients with suspected lung cancer.
Topics: Aged; Ambulatory Care; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Contrast Media; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Small Cell Lung Carcinoma; Tomography, X-Ray Computed | 2014 |
Pseudomesotheliomatous lung cancer mimicking mesothelioma on ¹⁸F-FDG PET/CT images: report of 2 cases.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Diagnosis, Differential; Fluorodeoxyglucose F18; Humans; Lung; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2013 |
The association of 18F-FDG PET/CT parameters with survival in malignant pleural mesothelioma.
Topics: Aged; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Radiopharmaceuticals; Tomography, X-Ray Computed | 2014 |
¹⁸F-FDG uptake on PET is a predictive marker of thymidylate synthase expression in patients with thoracic neoplasms.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adolescent; Adult; Aged; Aged, 80 and over; Antigens, CD34; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Dihydrouracil Dehydrogenase (NADP); Female; Fluorodeoxyglucose F18; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Microvessels; Middle Aged; Neovascularization, Pathologic; Neuroendocrine Tumors; Orotate Phosphoribosyltransferase; Positron-Emission Tomography; Radiopharmaceuticals; Thoracic Neoplasms; Thymidylate Synthase; Thymus Neoplasms; Tumor Suppressor Protein p53; Vascular Endothelial Growth Factor A; Young Adult | 2014 |
FDG PET/CT is useful for detecting infiltration to the port site in patients with malignant pleural mesothelioma.
Topics: Biopsy; Combined Modality Therapy; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Seeding; Neoplasm Staging; Pleural Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Thoracic Surgery, Video-Assisted; Tomography, X-Ray Computed; Vascular Access Devices | 2014 |
A case of pleural epithelioid sarcoma of proximal type presenting as malignant pleural mesothelioma.
Topics: Biomarkers, Tumor; Diagnosis, Differential; Fatal Outcome; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Pleural Neoplasms; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Sarcoma; Tomography, X-Ray Computed | 2013 |
Clinical utility of 18F-FDG positron emission tomography in malignant peritoneal mesothelioma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Peritoneal Neoplasms; Positron-Emission Tomography; Recurrence; Retrospective Studies; Sensitivity and Specificity; Treatment Outcome; Young Adult | 2016 |
Malignant peritoneal mesothelioma with lower extremity metastasis: PET/CT imaging.
Topics: Aged; Female; Femoral Neoplasms; Fluorodeoxyglucose F18; Humans; Lower Extremity; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Multimodal Imaging; Neoplasms, Second Primary; Peritoneal Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Sarcoma; Soft Tissue Neoplasms; Tomography, X-Ray Computed | 2015 |
Positron Emission Tomography/Computed Tomography for the Pleural Staging of Malignant Pleural Mesothelioma: How Accurate Is It?
Topics: Aged; Databases, Factual; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Multimodal Imaging; Neoplasm Staging; Pleural Neoplasms; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Retrospective Studies; Thoracoscopy; Tomography, X-Ray Computed | 2015 |
Characterization of hypoxia in malignant pleural mesothelioma with FMISO PET-CT.
Topics: Aged; Aged, 80 and over; Cell Hypoxia; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Misonidazole; Pilot Projects; Pleural Neoplasms; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals; Tomography, X-Ray Computed | 2015 |
A case report of metastasis of malignant mesothelioma to the retromolar trigone.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Calbindin 2; Cisplatin; Deoxycytidine; Diagnosis, Differential; Fatal Outcome; Fluorodeoxyglucose F18; Gemcitabine; Humans; Immunohistochemistry; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Mouth Neoplasms; Pemetrexed; Pleural Neoplasms; Positron Emission Tomography Computed Tomography; Radiography, Panoramic; Radiotherapy, Adjuvant | 2016 |
Intensity-modulated radiotherapy for relapsed malignant pleural mesothelioma.
Topics: Aged; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Neoplasm Recurrence, Local; Pleural Neoplasms; Positron Emission Tomography Computed Tomography; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated; Treatment Outcome; Tumor Burden | 2016 |
Optimal gross tumor volume definition in lung-sparing intensity modulated radiotherapy for pleural mesothelioma: an in silico study.
Topics: Aged; Computer Simulation; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung; Lung Neoplasms; Magnetic Resonance Imaging; Male; Mesothelioma; Mesothelioma, Malignant; Multimodal Imaging; Neoplasm Staging; Organ Sparing Treatments; Pleural Neoplasms; Positron Emission Tomography Computed Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated; Retrospective Studies; Survival Rate; Tumor Burden | 2016 |
Prognostic value of pretreatment volume-based quantitative
Topics: Adult; Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Glycolysis; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Multimodal Imaging; Positron Emission Tomography Computed Tomography; Prognosis; Proportional Hazards Models; Radiopharmaceuticals; Retrospective Studies; Tumor Burden | 2017 |
Metabolic response assessment with 18F-FDG-PET/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Pemetrexed; Pleural Neoplasms; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Response Evaluation Criteria in Solid Tumors; Treatment Outcome | 2017 |
Prognostic significance of metabolic response by positron emission tomography after neoadjuvant chemotherapy for resectable malignant pleural mesothelioma.
Topics: Aged; Cisplatin; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Metabolism; Middle Aged; Multimodal Imaging; Neoadjuvant Therapy; Neoplasm Staging; Pleural Neoplasms; Positron-Emission Tomography; Prognosis; Tomography, X-Ray Computed | 2013 |